Alanine aminotransferase elevations during triple therapy with simeprevir, pegylated interferon plus ribavirin
-
- Tahata Yuki
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Hiramatsu Naoki
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Oze Tsugiko
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Urabe Ayako
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Morishita Naoki
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Yamada Ryoko
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Yakushijin Takayuki
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Saji Yukiko
- Itami City Hospital
-
- Oshita Masahide
- Osaka Police Hospital
-
- Mita Eiji
- National Hospital Organization Osaka National Hospital
-
- Hagiwara Hideki
- Kansai Rousai Hospital
-
- Fukui Hiroyuki
- Yao Municipal Hospital
-
- Yamada Yukinori
- Kaizuka City Hospital
-
- Ito Toshifumi
- Japan Community Health Care Organization Osaka Hospital
-
- Hijioka Taizo
- National Hospital Organization Osaka Minami Medical Center
-
- Inada Masami
- Toyonaka Municipal Hospital
-
- Katayama Kazuhiro
- Osaka Medical Center for Cancer and Cardiovascular Diseases
-
- Tamura Shinji
- Minoh City Hospital
-
- Inoue Atsuo
- Osaka General Medical Center
-
- Imai Yasuharu
- Ikeda Municipal Hospital
-
- Hikita Hayato
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Sakamori Ryotaro
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Yoshida Yuichi
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Tatsumi Tomohide
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
-
- Hayashi Norio
- Kansai Rousai Hospital
-
- Takehara Tetsuo
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
Bibliographic Information
- Other Title
-
- シメプレビル/ペグインターフェロン/リバビリン併用療法の肝障害について
- シメプレビル/ペグインターフェロン/リバビリン ヘイヨウ リョウホウ ノ カン ショウガイ ニ ツイテ
Search this article
Abstract
In the clinical trials of triple therapy with simeprevir, pegylated interferon plus ribavirin, alanine aminotransferase (ALT) elevations have not been reported in detail during treatment. In the present study, we examined the frequencies and characteristics of ALT elevations in 321 chronic hepatitis C patients who were treated with triple therapy and became HCV-RNA negative during treatment. ALT elevations more than 100 U/L were observed in 5.0% (16/321) during treatment (100-200 U/L: 13 patients, 200-400 U/L: 2 patients, 400<U/L: 1 patient). Out of these patients, 8 patients showed that serum ALT levels rapidly increased between 8 and 12 weeks. All patients except one patient whose treatment was discontinued due to the marked elevation of ALT level (663 U/L), serum ALT levels decreased soon after simeprevir administration was finished. Periodic liver function tests were needed since ALT elevations can occur during simeprevir, pegylated interferon plus ribavirin therapy.
Journal
-
- Kanzo
-
Kanzo 56 (11), 567-574, 2015
The Japan Society of Hepatology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679771270400
-
- NII Article ID
- 130005112832
-
- NII Book ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- NDL BIB ID
- 026944666
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed